Product Description
PanKRAS inhibitor 2G for lung and GI cancers in preclinical development. (Sourced from: https://www.beigene.com/science/pipeline/)
Mechanisms of Action: KRAS Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BeiGene
Company Location: GRAND CAYMAN E9 KY1-1108
Company CEO: John V. Oyler
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|